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1. Introduction 
Melanoma-associated antigens are categorized as class I human leukocyte antigen (HLA)-
restricted cancer/testis antigens (Renkvist et al., 2001) which are considered to be 
immunogenic to the immune system because they are hardly expressed in normal tissues 
except testis. However, melanoma is still difficult cancer to treat once it becomes advanced 
or metastatic. Malignant melanoma is the most well known cancer in which multiple tumor-
specific antigens have been defined compared to other solid cancers, and utilized in 
vaccination strategies as peptide vaccines or peptide-pulsed dendritic cell (DC) vaccines 
(Nestle et al., 1998; Banchereau et al., 2001). Our group has been running a clinical phase I 
trial of peptide cocktail-pulsed DC vaccines in metastatic melanoma patients for some years. 
We reported that almost all cases showed more than 2 peptide-specific cytotoxic T cell (CTL) 
responses in blood and 2 cases had clinical responses [1 complete remission (CR), 1 partial 
remissions (PR)] (Akiyama et al., 2005).  
We have identified some melanoma peptide-specific CTL lines and determined cDNA 
sequences of specific TCRs in the clinical trial. However, few studies have focused on the 
characterization or determination of peptide-oriented single specific CTL clones from 
melanoma patients treated with DC vaccines. Recently, specific CTLs or tumor-infiltrating 
lymphocytes (TILs) have been successfully cloned from blood or tumors of melanoma 
patients (Dudley et al., 2001, 2002, 2005; Yee et al., 2002). In some cases, melanoma peptide-
specific CTL clones obtained from the tumor tissue were expanded, and could be utilized for 
adoptive immunotherapy (Dudley et al., 2002, 2005).  
Interestingly, it is also reported that the same TCR repertoire specific to MART-1 peptide 
was recognized among blood CTLs as TIL clones isolated from tumors. 
As to other types of cancers, a very small number of TILs were expanded to isolate tumor-
specific clones from a bulk of TILs and utilized to search for novel tumor antigens in a 
tumor-derived complementary DNA library (Hoshino et al., 1997; Gohara et al., 1997). 
However, cloning from a bulk of CTLs is time-consuming, and usually very costly.   
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In the present study, we have established a novel efficient method for the expansion and 
separation of a very small number of melanoma peptide-specific CTLs using HLA-A2 or 
A24 peptide tetramer and T cell receptor (TCR)-specific monoclonal antibody (MoAb)-based 
cell sorting. Through the molecular cloning of melanoma peptide (MART-1, gp100 or 
MAGE-1)-specific TCRs, the biological characterization of each CTL line was performed in 
Japanese metastatic melanoma patients given DC vaccines. 
2. Experimental design 
2.1 Clinical trial of DC vaccines 
Thirty-three cases of metastatic melanoma were enrolled into a phase I/II study of 
monocyte-derived DC-based immunotherapy. HLA typing showed 7 cases of HLA-A2 and 
26 of A24 positive. Briefly, Enriched monocytes were obtained using OptiPrepTM from 
leukapheresis products, and then incubated with GM-CSF and IL-4 in a closed serum-free 
system. After pulsing with a cocktail of 5 melanoma-associated synthetic peptides (gp100, 
tyrosinase, MAGE-2, MAGE-3 and MART-1 or MAGE-1) restricted to HLA-A2 or A24 and 
keyhole limpet hemocyanin (KLH), cells were cryopreserved until used. Finally, thawed 
DCs were washed and injected subcutaneously (s.c.) into the inguinal region in a dose-
escalation manner.  
2.2 CTL induction cultures  
Peripheral blood mononuclear cells (PBMCs) from 6 cases of HLA-A*0201+ and 1 of HLA-
A*2402+ metastatic melanoma were used for in vitro CTL inductions (The clinical research 
using PBMC from melanoma patients was approved by the Institutional Review Board of 
Shizuoka Cancer Center, Shizuoka, Japan. All patients gave written informed consent.). All 
cases of metastatic melanoma were given melanoma-associated peptide-pulsed DC vaccines 
in clinical trial reported previously (Akiyama et al., 2005). Briefly, after non-adherent 
PBMCs were stimulated twice with melanoma peptide-pulsed mature DCs (most cells 
positively stained with CD83 MoAb), cells were boosted in RPMI1640 medium containing L-
glutamine (2mM), penicillin (100U/ml), streptomycin (100U/ml) and 5% AB human serum 
referred to as CTL medium with 2 rounds of stimulation with peptide-pulsed T2 or T2-A24 
cells. Finally, expanded peptide-specific CTLs were utilized for various experiments or cell 
sorting. 
2.3 TCR repertoire profiling and function analysis 
The staining profile of CTLs during the expansion procedure was monitored using a TCR 
Vβ repertoire kit, major populations positively stained with the specific anti-TCR antibody 
were determined. For function analysis, CTLs were pre-incubated with melanoma peptide-
treated T2 or T2-A24 cells and stained intracellularly with anti-human IFN-γ MoAb, peptide-
specific tetramer, and/or anti-specific TCR MoAb. The stained cells were analyzed on a flow 
cytometer. 
2.4 CTL sorting by TCR-specific MoAb 
Melanoma peptide tetramer-based or TCR MoAb-based CTL sorting was performed using 
the autoMACS (magnetic cell sorting) system (Miltenyi, Germany). Briefly, we used a 
specific PE-labeled tetramer or FITC-labeled TCR-specific MoAb as primary antibody, and 
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anti-PE or FITC MoAb microbeads as secondary antibody. The purity of the tetramer+ or 
specific TCR+ CTLs was more than 98% (data not shown). Purified CTLs were sequentially 
used for PCR cloning of the TCR gene. 
2.5 PCR cloning and sequencing of melanoma peptide-specific TCRBV cDNA 
Total RNA of sorted CTLs was prepared with a kit, Nucleospin RNA II (Machery-Nagel, 
Germany), and aliquots of 2 μg were subjected to reverse transcription using oligo (dT) 
primer and SuperScript II (Invitrogen, CA). The first strand cDNA was amplified by PCR 
using KOD Polymerase (Toyobo, Japan) according to the manuacturer’s instructions. 
Coding region-specific primers for TCRBV28 and TCRBC1 (MART-1 peptide-specific TCR), 
TCRBV12-4 and TCRBC2 (gp100 peptide-specific TCR) or TCRBV4 and TCRBC1 (MAGE-1 
peptide specific TCR) are shown as in Table 1. 
 
TCRBV28;    5’-GCAGCCATGGGAATCAGGCTCCTCTGT-3’
TCRBV12-4; 5’-TCTGCCATGGACTCCTGGACCCTCTGC-3’ 
TCRBV4; 5’-GCTAGCATGGGCTGCAGGCTGCTCTGC-3’
TCRBC1; 5’-TCAGAAATCCTTTCTCTTGACCATGGC-3’
TCRBC2; 5’-CTAGCCTCTGGAATCCTTTCTCTTGAC-3’
Repertoire Sequence
Table 1 TCR-specific primers
 
Table 1. TCR-specific primers 
The PCR product was separated by electrophoresis on a 1.5% agarose gel, and the band of 
appropriate size (bp) was excised and extracted from the gel. The recovered DNA fragment 
was cloned into the plasmid pCR-Blunt (Invitrigen, CA, USA), and its sequence was 
determined using BigDye Terminator reagent and a 3130xl Genetic Analyzer (Applied 
Biosystems, CA).  
2.6 TCRBV gene transduction into primary naive T cells 
The plasmid vector pmax was utilized for making the construct containing GFP, cloned 
specific TCR genes, or vehicle. T cell transfection kit (NucleofectorTM, Amaxa, Cologne, 
Germany) and a NucleofectorTM device (Amaxa) were used according to the manufacturer’s 
instructions. Prior to electroporation, all lymphocytes including T cells were usually 
stimulated with anti-CD3 (2ug/ml) and CD28 MoAb (1ug/ml) for 5 days in GT-T503 
medium and collected for the gene transduction procedure. The expression of TCR protein 
was analyzed on a flow cytometer using anti-TCRBV9 and BV28 (in MART-1) or anti-
TCRBV12 (in gp100) MoAbs. 
2.7 IFN-γ production by specific TCR gene-transduced naïve T cells 
Two days after electroporation, naïve T cells transduced with mock, GFP, or a specific TCR 
gene were harvested and incubated with melanoma peptide-pulsed T2 cells or TISI cells for 
24 hours. The supernatant was collected and the IFN-γ level was measured using an ELISA 
kit specific for human IFN-γ.  
www.intechopen.com
 
Breakthroughs in Melanoma Research 
 
498 
3. Result 
3.1 Tetramer
+
 CTL induction and expansion 
After the expansion of melanoma peptide-specific CTLs, the frequency of MART-1 tetramer+ 
CTLs increased to 46.5 % (mean of 4 cases) compared with before stimulation (less than 1%) 
(Table.2). The absolute No. of MART-1 tetramer+ CTLs was shown to increase 187 to 619 fold 
(average 415 fold) after T2 stimulations compared to prior to the stimulation. Additionally, 
in case 3 and 5, gp100 A2 and MAGE1 A24 tetramer+ CTLs were surprisingly expanded up 
to 1585 and 5068 fold, respectively. 
 
Case 
No.
Total cell No. (x10
7
)
Pre 2DC 2DC+2T2
a
tetramer (%)
Pre 2DC 2DC+2T2
a
Pre; before starting CTL induction, 2DC; after 2 rounds of  peptide-pulsed DC stimulation,
2DC+2T2; after 2 rounds of peptide-pulsed T2 stimulation in addition to 2DC, N.D.; not detected,
Each value shows the mean for 2 experiments. 
a
In case5, T2-A24 cells treated with MAGE1 A24
peptide  were used.  
b
Expansion data from gp100 A2 peptide-stimulated CTLs. Values in the 
parenthesis show fold increase of tetramer+ CTL No. compared with pre-stimulation.
Peptide
2.41 2.5 2.0 0.14 (1) 0.89 (66) 31.7 (186)MART1 (A2)
2.03
b
9.3 - 0.13 (1) 44.3 (1585) -gp100 (A2)
2.05 12.3 21.8 0.04 (1) 3.1 (477) 18.6 (5068)MAGE1 (A24)
2.02 3.6 3.9 0.35 (1) 4.64 (24) 78.8 (396)MART1 (A2)
2.03 2.2 4.8 0.12 (1) 1.73 (19) 40.5 (619)MART1 (A2)
2.04 1.4 0.62 0.02 (1) 1.32 (46) 35.0 (458)MART1 (A2)
 
Table 2. Analysis of peptide-specific CTL production from melanoma patients 
3.2 CTL killing activity of expanded melanoma peptide-specific CTLs 
Cultured CTLs from 4 melanoma cases showed strong killing activity against MART-1 
peptide-pulsed T2 cells and the C32 melanoma cell line (HLA-A*0201+, MART1+) (Fig. 1A). 
In contrast, no significant killing activity was seen in RPMI7951 (HLA-A*0201+, MART1-) 
and NCC-KT (HLA-A*0201-, MART1+). The killing activity was shown to be HLA-A2 and 
antigen (MART-1)-specific. Meanwhile, MAGE-1 A24 peptide-CTLs induced from case 5 
were also demonstrated to be HLA-A24 and MAGE-1 antigen-specific in killing against TISI 
and cancer cell lines (Fig. 1B).  
3.3 Intracellular IFN-γ staining of expanded tetramer+ CTLs from melanoma patients  
The frequency of both MART-1 tetramer and IFN-γ-positive CTLs in 4 melanoma cases after 
peptide-pulsed T2 stimulation was 7.6%, 34.2%, 25.4%, and 9.8%, respectively. The percentage 
of IFN-γ+ out of all tetramer+ cells was 23.9%, 43.4%, 62.7% and 27.9%. CTLs from case 2 and 
3 were more efficient in IFN-γ production than those from the other two cases (Fig. 2). In the 
case of MAGE-1 A24 CTLs, 49% of tetramer+ cells were shown to be IFN-γ producer. 
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                                                 (A)                                                                                (B) 
Fig. 1. Cytotoxic activity of expanded melanoma peptide-specific CTL lines from melanoma 
patients. Target cells were labeled with fluorescence enhancing ligand and co-incubated 
with CTLs for 3 hrs. (A) MART1-specific CTL lines from 4 cases, T2 (-); untreated, T2 (+); 
treated with MART1 A2 peptide, melanoma cell lines (C32 : HLA-A*0201+, MART1+ ; 
RPMI7951 : HLA-A*0201+, MART1- ; NCC-KT : HLA-A*0201-, MART1+). (B) MAGE1-specific 
CTL line from case 5, LN-18: HLA-A*2402+, MAGE1+ ; HT-29 : HLA-A*2402+, MAGE1-. Each 
column shows the mean ± S.D. for triplicate samples 
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                         (A)                                                (B)                                                  (C) 
Fig. 2. IFN-γ production from melanoma peptide tetramer+ CTL lines stimulated with 
peptide-pulsed target cells. Each CTL line was stained first with MART-1 A2 or MAGE-1 
A24 peptide tetramer and then intracellularly with anti-IFN-γ MoAb. (A) case 2, (B) case 3 
and (C) case 5 
3.4 TCR repertoire profiling in melanoma cases and its relation to cytotoxic activity  
After the expansion there were 1 major and 3 minor populations with specific TCR 
repertoires among 78.8 % of MART-1 tetramer+ CTLs in case 2 (Table. 3). Case 3 had a major 
population in both MART-1 and gp100 A2 tetramer+ CTLs. In the case 5 of MAGE-1 A24 
tetramer+ CTLs, 2 major populations were identified. Fig. 3 shows the association of IFN-γ 
production by peptide-stimulated CTLs (cytotoxic activity) with the specific TCR repertoire 
in cases 2 and 5. TCRBV9+ (MART1) CTL populations alone exhibited a specific killing activity 
in case 2 (Fig. 3A). TCRBV28+ (MART1) and BV12+ (gp100) in case 3, TCRBV4+ (MAGE1) in 
case 5 (Fig. 3B), were identified as IFN-γ producers. Those populations were specifically 
sorted (purity >98%) using the autoMACS system, and utilized for TCR gene cloning. 
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Fig. 3. IFN-γ production by CTL populations recognized by specific anti-TCR repertoire 
MoAb. (A) MART-1 A2 peptide-specific CTLs. MoAbs for TCRBV9, TCRBV20,, TCRBV4 and 
TCRBV27 were used. (B) MAGE-1 A24 peptide-specific CTLs. MoAbs for TCRBV4 and 
TCRBV5 were used. Each CTL was stained first with anti-TCR repertoire MoAb and then 
intracellularly with anti-IFN-γ MoAb after target cell stimulation 
3.5 IFN-γ production from peptide-specific CTL line sorted by TCR-specific MoAb 
CTL lines sorted by FITC-labeled anti-TCRBV28, anti-TCRBV12 or anti-TCRBV4 MoAbs 
showed MRAT-1, gp100 and MAGE-1 peptide specific cytotoxic activity, respectively  
(Fig. 4). Gp100 A2-peptide specific CTL line exhibited the greater IFN-γ production than 
other peptide-specific lines after the various dose of peptide-pulsed target cell 
stimulation. 
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Case 
No.
Peptide Repertoire Frequency* 
(%)
MART12 BV9 35.7
18.5
12.1
MART13 87.8
gp1003 82.5
*Frequency ; percentage of tetramer+/specific TCR repertoire+ CTLs. 
A  TCR repertoire with a frequency of more than 10% was chosen.  
Each value shows the mean for 2 experiments.
11.3
BV20
BV4
BV27
BV28
BV12
Tetramer+
CTLs (%)
78.8
40.5
44.3
MAGE15 27.1BV418.4
12.8BV5
 
Table 3. Frequency of specific TCR repertoire+ CTLs from melanoma patients 
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Fig. 4. Peptide dose-dependent IFN-γ productions from anti-TCR MoAb-sorted CTL lines. 
(A) Anti-TCRBV28 MoAb-sorted MART-1-specific CTL line, (B) anti-TCRBV12 MoAb-sorted 
gp100-specific CTL line, (C) anti-TCRBV4 MoAb-sorted MAGE-1-specific CTL line. These 
lines were stimulated with peptide-treated target cells. IFN-γ levels in the supernatant were 
measured using human IFN-γ-specific ELISA kit. Each point shows the mean ± S.D. of 
triplicate samples   
3.6 TCR cDNA sequences in melanoma peptide-specific CTL lines 
Cloned TCR cDNA sequences are shown in Fig. 5 (MART-1-specific sequence in case2, 
MART-1, gp100-specific sequence in case3 and MAGE1-specific sequence in case5). The TCR 
repertoire used was TCRBV9 in case 2, TCRBV28 and TCRBV12 in case 3, and TCRBV4 in 
case 5, respectively. 
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Case3 gp100 A2 CTL
Case3 MART-1 A2 CTL
Case2 MART-1 A2 CTL
Repertoire          TRBV9*01            N1  TRBD2*01  N2    P         TRBJ2-7*01
Nucleotide   tgtgccagcagcgtag ... gg ... gcgg  ..... tc .. ag...ctcctacgagcagtacttc 
Protein         C  A    S    S   V   G              A    V              S       S   Y   E   Q  Y    F
Repertoire    TRBV28*01      N1    TRBD1*01        N2          TRBJ1-5*01
Nucleotide   tgtgccagcag....CC....cagggggc....ctgggc.....cagccccagcatttt 
Protein         C  A   S    S         P          G   G          L  G          Q   P   Q   H  F
Repertoire     TRBV12-4*01         TRBD1*01    N2          TRBJ2-2*01
Nucleotide   tgtgccagcagtttagc.....aggggg.....tt.....acaccggggagctgtttttt
Protein         C   A   S   S L  A          G  G Y          T    G    E   L  F F
Case5 MAGE-1 A24 CTL
Repertoire         TRBV4-1*01          N1    P    TRBD1*01  N2    P        TRBJ1-1*01
Nucleotide   tgcgccagcagccaag...tt ... cc ... gggacag....atg....a...tgaacactgaagctttcttt
Protein          C   A   S    S    Q      V        P         G  Q          M          M  N   T   E    A   F  F
 
Fig. 5. Alignment of cloned TCR cDNA sequences from sorted CTL lines. Segments V, D, J and 
C were identified using a tool at the IMGT web site (JunctionAnalysis, http://imgt.cines.fr/) 
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                                                   (A)                                                (B) 
Fig. 6. GFP gene transduction into melanoma patients’ PBMCs using electroporation. After 
electroporation, cells were stained with anti-CD3 MoAb and analyzed on a flow cytometer. 
(A) Stimulated PBLs, (B) picture of PBLs expressing GFP. PBLs stimulated with anti-CD3 
and anti-CD28 MoAb prior to electroporation 
3.7 TCR cDNA transduction into primary naïve T cells in melanoma cases 
The GFP cDNA transduction experiment after antibody-mediated T cell stimulation showed 
an improved transduction efficiency [unstimulated 25.9% (data not shown) vs stimulated 
40.1%] (Fig. 6A). In the case of 4μg of the TCR cDNA for MART-1, gp100 and MAGE-1, the 
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frequency of TCR-positive T Cells was 23.9% (MART-1, case2), 31.3% (MART-1, case3), 
13.3% (gp100, case 3) and 32.4% (MAGE-1, case 5), respectively (data not shown).  
3.8 IFN-γ production by TCR cDNA-transduced naïve T cells on peptide stimulation 
PBMCs from melanoma patients were transduced with 4 μg of TCR cDNA (MART-1 in 
case2 and 3, gp100 in case3 and MAGE-1 in case 5) by electroporation and used for co-
culture with peptide-pulsed target cells. PMBCs transduced with the MART-1-specific TCR 
cDNA (case 3) showed specific IFN-γ production against MART-1 peptide-pulsed T2 cells in 
a HLA and antigen-restricted manner (Fig. 7). Additionally, PBMCs transduced with another 
MART-1-specific (case 2), gp100-specific (case 3) and MAGE1-specific (case 5) TCR cDNAs 
also demonstrated moderate IFN-γ production against each of the peptide-pulsed target 
cells. 
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Fig. 7. IFN-γ production from specific TCR cDNA-transduced PBLs derived from a 
melanoma patient against target cells. Mock or TCR gene-transduced PBLs were co-
incubated with peptide-treated target cells. (A) MART-1 or gp100 A2 peptide-specific CTLs 
from melanoma case 2 and 3. (B) MAGE-1 A24 peptide-specific CTL from melanoma case 5. 
The amount of IFN-γ produced in the supernatant was measured using an ELISA kit. T2 (-); 
untreated, T2 (peptide); treated with various peptides. Each column shows the mean ± S.D. 
for triplicate samples. * * ; P< 0.01, * ; P<0.05 
4. Discussion 
It is generally considered that spontaneously immunized CTL clones can be recognized at 
tumor sites or in peripheral blood without aggressive vaccinization, because melanomas are 
generally immunogenic tumors in terms of the immune response against antigens 
(Mandruzzato et al., 2002; Sensi et al., 1995). With regard to common melanoma antigens 
like MART-1, gp100, and tyrosinase and MAGEs, many heterogenous tumor-infiltrating 
lymphocytes (TILs) or blood CTLs specific to these peptides have been identified using 
clonal analysis and characterized specifically in terms of antigen avidity and cytotoxic 
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activity against tumors (Valmori et al., 2000; Sensi et al., 1993; Yee et al., 1999; Hishii et al., 
1997).  
This time we characterized melanoma antigen-specific CTL lines derived from the blood of 
patients given DC vaccines and established an ex vivo expansion culture method. Finally, 
our group succeeded in cloning and sequencing melanoma peptide (MART-1, gp100, and 
MAGE-1)-specific TCR genes. Few clonal CTL analyses after the use of cancer vaccines 
including DCs and peptides have been performed so far (Valmori et al., 2002; Kan-Mitchell 
et al., 1993; Powell et al., 2006) Powell et al. demonstrated the efficacy of a multiple course 
peptide-immunization for the generation in high frequencies of tumor antigen-specific T 
cells, because they recognized vaccine-specific CTLs in blood even one year after the final 
vaccination (Powell et al., 2004). Additionally, Godelaine et al. reported that several potent 
CTL clones specific to MAGE3 A1 peptide were amplified after the use of a peptide-pulsed 
DC vaccine and the frequency of tetramer-positive CTLs in blood increased 20-400 fold 
compared with before the vaccination (Godelaine et al., 2003).  
With regard to ex vivo CTL expansion, we established our own method to increase number 
of melanoma-peptide-specific blood CTLs from patients given a DC vaccine several times. 
Briefly, PBMCs obtained from melanoma patients were stimulated in vitro with patient-
derived DCs pulsed with the same peptide as used in the DC vaccine, and furthermore 
activated with peptide-pulsed target cells like T2 and T2-A24. Finally, MART-1 and MAGE-
1 tetramer-positive CTLs were able to be expanded up to 620 and 5070 fold, respectively in 
melanoma patients given the vaccine. In contrast, in the case of CTLs obtained from patients 
prior to the vaccination, the expansion was much less extensive. This observation 
demonstrated that utilizing PBMCs from vaccinated patients is a very efficient way of 
preparing numerous adoptive CTLs for clinical use. More importantly, MAGE-1 A24 
peptide-specific CTL line was derived from a DC vaccinated-patient who showed a 
significant clinical response, and our group succeeded in cloning and sequencing of MAGE-
1 A24 peptide-specific T cell receptor (TCR) cDNA for the first time. 
Meanwhile, distinguishing these CTLs in terms of tumor-specific avidity and cytotoxicity is 
important. Generally, tetramer-positive CTLs have polyclonal effectors and the clone 
responsible for the genuine anti-tumor activity cannot be identified at the expansion stage. 
We utilized specific staining of CTLs with a combination of anti-TCR MoAb and 
intracellular IFN-γ staining. Using this method, the monoclonal TCR repertoire mediating 
the anti-tumor cytotoxicity could be elucidated. Furthermore, anti-TCR MoAb-sorted CTL 
clones were shown to have the very potent melanoma-peptide specific cytotoxic activity. 
Once the functional TCR repertoire is determined, a functional CTL clone can be purified by 
MoAb sorting, and finally specific DNA is cloned as we have performed. This might be a 
novel approach to determine the genuine clone responsible for peptide-specific cytotoxicity 
at the level of selection of polyclonal CTLs (Fig. 8).  
Demonstrating the efficiency and capability of cancer-specific CTLs for clinical application is 
also important issue. Many studies of cytotoxicity or avidity for tumors comparing TILs 
with blood CTLs have been reported. Basically, TIL clones tend to be more cytotoxic and 
have greater affinity for tumor cells and a more limited TCR repertoire than blood CTLs. 
Cole et al. and others showed that the same TCR repertoire specific to MART-1 peptide was 
recognized among blood CTLs as TIL clones isolated from tumors, which supported the 
application of vaccine-boosted blood CTLs to adoptive immunotherapy (Cole et al., 1997). In 
the present study, TILs from melanoma tissue were not analyzed. In future, upcoming 
resected tumors will be used for TIL expansion according to other researchers’ methods. 
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Fig. 8. Strategy for vaccinated patients-based immune-effector cell engineering for developing 
a novel adoptive CTL therapy 
When considering the application of native adoptive CTL therapy, a great number of potent 
CTLs specific to cancer peptides are needed. The technology of TCR gene-engineering is 
possibly one efficient tool with which to expand necessary specific effector T cells. Recently, 
retroviral vector-mediated TCR gene transduction has been utilized in basic research and 
some clinical trials (Roszkowski et al., 2005; Hughes et al., 2005; Morgan et al., 2006; Tsuji et 
al., 2005). Recently, the use of a lentiviral vector system was shown to be the optimal way to 
transduce specific TCR genes into naïve T cells (Van Tendeloo et al., 2007). However, 
adverse effects such as leukemogenesis in stem cell-based retroriral gene transduction 
programs cannot be avoided completely. In the present study, a novel electroporation-based 
TCR gene transduction was performed and the transduction efficiency in naïve T cells 
derived from melanoma patients was acceptable (56% for GFP gene, 31% for MART-1 
TCRBV28 gene, respectively). More importantly, anti-CD3 and anti-CD28 antibody-
mediated T cell activation prior to electroporation is needed to reduce the damage to T cells 
and promote the transduction efficiency as previously reported (Chun et al., 2002).  
DC vaccine-based efficient CTL expansion using blood CTLs from vaccinated melanoma 
patients, may be a good immunotherapeutic modality. This novel approach can be 
employed for adoptive CTL therapy followed by the use of peptide-cocktail pulsed DC 
vaccines and the administration of a T cell-supporting cytokine like IL-2, IL-7 or IL-15 to 
maintain and expand infused CTLs in vivo. 
5. Conclusion 
We characterized melanoma antigen-specific CTL lines derived from the blood of patients 
given DC vaccines and established an ex vivo expansion culture method. For functional 
analysis of CTLs, specific staining of CTLs with a combination of anti-TCR MoAb and 
intracellular IFN-γ staining was utilized, and monoclonal TCR repertoire mediating the anti-
tumor cytotoxicity was able to be elucidated. Anti-TCR MoAb-sorted CTL clones were 
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shown to exhibit the very potent melanoma-peptide specific cytotoxic activity. Finally, we 
succeeded in cloning and sequencing melanoma peptide (MART-1, gp100, and MAGE-1)-
specific T cell receptor (TCR) genes. This might be a novel approach to determine the 
genuine clone responsible for peptide-specific cytotoxicity at the level of selection of 
polyclonal CTLs.     
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